BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 18292508)

  • 1. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
    Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
    J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
    Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
    J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
    Uchida J; Hamaguchi Y; Oliver JA; Ravetch JV; Poe JC; Haas KM; Tedder TF
    J Exp Med; 2004 Jun; 199(12):1659-69. PubMed ID: 15210744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
    Tedder TF; Baras A; Xiu Y
    Springer Semin Immunopathol; 2006 Dec; 28(4):351-64. PubMed ID: 17091246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice.
    Makhlouf L; Grey ST; Dong V; Csizmadia E; Arvelo MB; Auchincloss H; Ferran C; Sayegh MH
    Transplantation; 2004 Apr; 77(7):990-7. PubMed ID: 15087759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated B7-1 and B7-2 expression on nonobese diabetic mouse B cells is associated with increased T cell costimulation and the development of insulitis.
    Hussain S; Delovitch TL
    J Immunol; 2005 Jan; 174(2):680-7. PubMed ID: 15634886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy.
    Wang Q; Racine JJ; Ratiu JJ; Wang S; Ettinger R; Wasserfall C; Atkinson MA; Serreze DV
    J Immunol; 2017 Dec; 199(11):3757-3770. PubMed ID: 29055002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
    Hamaguchi Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):29-34. PubMed ID: 19252375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
    Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
    Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.
    Sarikonda G; Sachithanantham S; Manenkova Y; Kupfer T; Posgai A; Wasserfall C; Bernstein P; Straub L; Pagni PP; Schneider D; Calvo TR; Coulombe M; Herold K; Gill RG; Atkinson M; Nepom G; Ehlers M; Staeva T; Garren H; Steinman L; Chan AC; von Herrath M
    PLoS One; 2013; 8(2):e54712. PubMed ID: 23405091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies.
    Serreze DV; Chapman HD; Niens M; Dunn R; Kehry MR; Driver JP; Haller M; Wasserfall C; Atkinson MA
    Diabetes; 2011 Nov; 60(11):2914-21. PubMed ID: 21926271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.
    Minard-Colin V; Xiu Y; Poe JC; Horikawa M; Magro CM; Hamaguchi Y; Haas KM; Tedder TF
    Blood; 2008 Aug; 112(4):1205-13. PubMed ID: 18495955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell depletion reduces T cell activation in pancreatic islets in a murine autoimmune diabetes model.
    Da Rosa LC; Boldison J; De Leenheer E; Davies J; Wen L; Wong FS
    Diabetologia; 2018 Jun; 61(6):1397-1410. PubMed ID: 29594371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development.
    Gregori S; Giarratana N; Smiroldo S; Adorini L
    J Immunol; 2003 Oct; 171(8):4040-7. PubMed ID: 14530324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice.
    Haas KM; Watanabe R; Matsushita T; Nakashima H; Ishiura N; Okochi H; Fujimoto M; Tedder TF
    J Immunol; 2010 May; 184(9):4789-800. PubMed ID: 20368280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell depletion: a novel therapy for autoimmune diabetes?
    Bour-Jordan H; Bluestone JA
    J Clin Invest; 2007 Dec; 117(12):3642-5. PubMed ID: 18060022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.
    Hu CY; Rodriguez-Pinto D; Du W; Ahuja A; Henegariu O; Wong FS; Shlomchik MJ; Wen L
    J Clin Invest; 2007 Dec; 117(12):3857-67. PubMed ID: 18060033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors.
    Christianson SW; Shultz LD; Leiter EH
    Diabetes; 1993 Jan; 42(1):44-55. PubMed ID: 8093606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.
    Lenschow DJ; Ho SC; Sattar H; Rhee L; Gray G; Nabavi N; Herold KC; Bluestone JA
    J Exp Med; 1995 Mar; 181(3):1145-55. PubMed ID: 7532678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.